Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in TLT?
Theralase Technologies Inc.: THE INVESTMENT CASE

Laser specialist TheraLase Technologies primed for a pivotal year

Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years.
Laser specialist TheraLase Technologies primed for a pivotal year
INVESTMENT OVERVIEW: TLT The Big Picture
Cold laser technology uses light to penetrate tissue to promote cellular regeneration
TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) has developed laser products to heal tissue and treat pain, although its long-term value probably lies with an early-stage, light-activated treatment for cancer.
 
Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years. A market capitalization of $43mln suggests investors are yet to fully recognize the huge potential of this hybrid business.
 

Therapeutic Laser Technology 

 
This is cold laser technology that uses light to penetrate tissue to promote cellular regeneration at the source of the injury. It effectively heals patients by eliminating pain, reducing inflammation and accelerating tissue healing.
 

WATCH: Here’s how it works 

 
The equipment is used by doctors and other healthcare professionals and the company has around 600 TLC-1000 systems installed in Canada and 400 a further in the US and internationally.  The TLC-2000 is its next-
generation product backed by eight patents. 
 
Last year its kit, which is leased out, generated sales of $2mln. However, chief executive Roger Dumoulin-White reckons there is room for exponential revenue growth. 
 
“If you look at the Canadian and US market, so you’re looking at doctors, chiropractors, hospitals, physical therapists, you know, that type of grouping of individuals, there’s about 1.65mln in North America or in Canada and
the United States,” Dumoulin-White said in a recent interview with James West of the Midas Letter. 
 
“So at an average sale price in the $25,000 range, it quickly runs into the billions of dollars of potential for the technology.”
 
The TheraLase boss thinks the business could be generating $30-$50mln annually in the next three to five years.
 

Photo Dynamic Therapy

 
The company is developing light activated photo dynamic compounds (PDCs) to destroy cancer. This is where the compound is absorbed by the tumour and activated by light.
 
A phase Ib clinical study in Canada for non-invasive bladder cancer was expected to commence in the fourth-quarter of last year focusing on a small group of patients. The first-in-man study of TLD 1433, a water-soluble molecule, is designed to assess safety and tolerability rather than efficacy.
 
A catheter will be used to fill patients’ bladders with the drug, which is left in situ for 60 minutes to allow it to localize into the cancer lesions.
 
The area is then flushed before a fibre optic bundle is inserted to illuminate the bladder with a green laser light. This activates the drug that destroys the cancer. 
 
While uncomfortable, it is far less painful and invasive than the alternative treatments, which have patchy success rates.
 
“It’s very, very exciting technology if we can make this work,” said Dumoulin-White.

 

Phase Ib study 

 
Later this quarter, TheraLase expects to move the research and development process up a gear with an investigational new drug application to the Food & Drug Administration for a Phase II clinical study in the US. 
 
While it is still early days for the technology, peer-reviewed preclinical results have been impressive.
 
“The drug has performed beyond our expectations as far as safety, tolerability and efficacy,” said Dumoulin-White. 
 
“We’ve seen virtually 99 to 100% kill across a wide range of cancers. 
 
“We’ve tried this on brain cancer, breast cancer, colorectal cancer, pancreatic cancer, prostate cancer. Same results: 100% kill, virtually no toxicity to healthy tissue.”

 

Immune response

 
Researchers have even seen what’s called an immune-mediated response.
 
That means the laser-activated drug has prevented the recurrence of cancer by teaching the immune system how to recognize the signature of those cancer cells.
 
“So it’s a very exciting technology,” said Dumoulin-White. 
 
“Having said all that, everyone’s head over heels about it, the scientists, the peer reviewed publications, our scientists and clinicians. 
 
“Having said that, we haven’t tried it humans yet.”
Ian_55ae0ddd437b7.jpg


Register here to be notified of future TLT Company articles
View full TLT profile

Theralase Technologies Inc. Timeline

Related Articles

Green pallet
January 11 2017
The company's holistic approach to the supply chain is proving disruptive, and particularly popular with the perishable food industry
Call service droids
March 09 2017
Between now and 2018, Panmure Gordon sees a compound annualised growth rate for profit in excess of 100%
MicroTrench.jpg
January 26 2017
Industry-leading technology and execution put Lite Access Technologies in a class all its own

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.